Paraproteinemic Renal Diseases that Involve the Tubulo-Interstitium

Department of Pathology, St. Louis University, St. Louis, Mo., USA.
Contributions to nephrology (Impact Factor: 1.53). 02/2007; 153:105-15. DOI: 10.1159/000096763
Source: PubMed

ABSTRACT The renal response to deposition of monoclonal light chains represents a spectrum of pathologic changes that can be divided into glomerular or tubulo-interstitial processes. Involvement of the tubulo-interstitium can include activation of the proximal tubule, proximal tubule injury/cell death, and cast nephropathy. In these diseases, the culprit is not the intact immunoglobulin protein but instead the immunoglobulin light chain. Recent noninvasive tests, including immunofixation electrophoresis or quantification of serum free light chains, have increased the sensitivity for detection of an abnormality in circulating free light chains and are invaluable ancillary tools, but short of renal biopsy, the diagnosis of these diseases can prove challenging. A description of the pathobiology and overview of the approach to management of these light chain-mediated renal lesions is provided.

Download full-text


Available from: Paul W Sanders, Jul 30, 2015
  • Source
    • "As a consequence, large amounts of FLCs reach the distal tubule lumen where they interact specifically with Tamm-Horsfall proteins (THPs; also known as uromodulin), generating myeloma casts. Cast formation in the distal tubule can block glomerular flow and cause proximal tubular atrophy [19], also contributing to interstitial fibrosis [20]. Simultaneously, the massive reabsorption of monoclonal FLCs within the proximal tubules induces proximal tubule cells apoptosis and DNA degradation, resulting in critical morphologic changes, such as epithelial-to-mesenchymal transition (EMT) or necrosis [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The spectrum of kidney disease-associated monoclonal immunoglobulin and plasma cell malignancies is remarkably broad and encompasses nearly all nephropathologic entities. Multiple myeloma with kidney impairment at presentation is a medical emergency since the recovery of kidney function is associated with survival benefits. In most cases, kidney impairment may be the first clinical manifestation of malignant plasma cell dyscrasias like multiple myeloma and light chain amyloidosis. Multiple myeloma per se cannot be considered a main risk factor for developing acute kidney injury following intravascular administration of iodinated contrast media. The risk is increased by comorbidities such as chronic kidney disease, diabetes, hypercalcemia, dehydration, and use of nephrotoxic drugs. Before the administration of contrast media, the current recommended laboratory tests for assessing kidney function are serum creatinine measurement and the estimation of glomerular filtration rate by using the CKD-EPI equation. The assessment of Bence Jones proteinuria is unnecessary for evaluating the risk of kidney failure in patients with multiple myeloma, since this test cannot be considered a surrogate biomarker of kidney function.
    BioMed Research International 04/2014; 2014:167125. DOI:10.1155/2014/167125 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mononoclonal gammopathies are not unfrequent in people over 50 years old (3,2 %). At presentation about half of them are classified as MGUS (monoclonal gammopathy of undetermined significance) whereas only 25 % have clinically documented plasma cell dyscrasias (myeloma, Waldenström macroglobulinemia or amyloidosis). MGUS has a 1 % per year risk of progression to such plasma cell malignant disorders. Establishing the diagnosis of monoclonal gammopathy requires immunofixation of serum and urine. Serum free light chain (fFLC) assay is a recently available test for diagnosis and monitoring patients with those plasma cell dyscrasias. The used antisera are specific for hidden épitopes on light chains bound to the heavy chain in the intact immunoglobulin, but exposed on the free light chains. Abnormal calculated serum κ/λ ratio is assumed to give information on large monoclonal production excess. In clinical context with absence or minimal monoclonal immunoglobulin marker, such as light chain multiple myeloma, non-secretory multiple myeloma, amyloidosis and light chain deposition disease, fFLC has proven to be a useful laboratory test. For the more frequent plasma cell dyscrasias (multiple myeloma with intact immunoglobulin, MGUS) the clinical utility of the fFLC for diagnosis and monitoring needs more extensive prospective studies to be established.
    Revue Francophone des Laboratoires 08/2008; 2008(404):37–50. DOI:10.1016/S1773-035X(08)71559-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal impairment is a common complication of multiple myeloma. Chronic renal failure is classified according to glomerular filtration rate as estimated by the MDRD (modification of diet in renal disease) formula, while RIFLE (risk, injury, failure, loss and end-stage renal disease) and AKIN (acute renal injury network) criteria may be used for the definition of the severity of acute renal injury. Novel criteria based on estimated glomerular filtration rate measurements are proposed for the definition of the reversibility of renal impairment. Renal complete response (CRrenal) is defined as sustained (i.e., lasting at least 2 months) improvement of creatinine clearance (CRCL) from under 50 mL/min at baseline to 60 mL/min or above. Renal partial response (PRrenal) is defined as sustained improvement of CRCL from under 15 mL/min at baseline to 30 to 59 mL/min. Renal minor response (MRrenal) is defined as sustained improvement of the baseline CRCL of under 15 mL/min to 15 to 29 mL/min or, if baseline CRCL was 15 to 29 mL/min, improvement to 30 to 59 mL/min. Bortezomib with high-dose dexamethasone is considered the treatment of choice for myeloma patients with renal impairment and improves renal function in most patients. Although there is limited experience with thalidomide, this agent can be administered at the standard dosage to patients with renal failure. Lenalidomide, when administered at reduced doses according to renal function, is effective and can reverse renal impairment in a subset of myeloma patients.
    Hematology 01/2010; 2010:431-6. DOI:10.1182/asheducation-2010.1.431 · 2.86 Impact Factor
Show more